Beyond Artificial Intelligence. Into Quantum Intelligence.
QIC combines quantum computing, artificial intelligence and deep domain expertise to build a new generation of industrial intelligence—and turn it into solutions and proprietary assets across drug discovery and finance.
01 / Who We Are
Building the next generation of industrial intelligence.
QIC was created to move beyond the limits of conventional computing and lead high-value transformation in drug discovery and finance. We develop Quantum–AI technologies, apply them to critical industry bottlenecks and convert their capabilities into scalable solutions, validated outcomes and proprietary assets.
From scientific capability to market-making value
Our ambition is not limited to advancing quantum research. QIC is building technologies and business models capable of changing how complex industrial decisions, discoveries and optimizations are made.
Focused where the value is greatest
We concentrate on drug discovery and finance—two fields where computational complexity, economic value and the need for domain expertise converge.
OUR BEGINNING
From understanding complex systems to changing real-world outcomes.
Choi Hwan-ho · Founder & CEODuring his research years at the University of Oxford
QIC began with a belief that advanced science should do more than explain the world—it should help change real outcomes. After years in academic research, founder Choi Hwan-ho turned his attention to drug discovery, where long development cycles, high failure rates and unresolved molecular complexity continued to limit progress.
His research into molecular electron distributions offered a different starting point: understanding biological behavior through the underlying physics and chemistry that govern it. That work became the foundation of QIC’s technology and continues to shape its approach today—combining quantum methods, artificial intelligence and domain expertise to address complex problems with measurable industrial value.
Science creates its greatest value when it changes real-world outcomes.QIC · FOUNDING PERSPECTIVE
02 / What Makes QIC Different
More than algorithms. A complete system for industrial value creation.
QIC combines frontier computing, deep domain knowledge, real-world validation and proprietary assets within one operating model.
01INTEGRATION
Quantum–AI Integration
We determine where quantum methods can create value and integrate them with AI and conventional computing.
02EXPERTISE
Deep Domain Expertise
Internal expertise in drug discovery and finance enables QIC to define the right problem, data and validation criteria.
03VALIDATION
Real-World Validation
Industry PoCs, joint development and proprietary programs validate technology against real data and outcomes.
04VALUE MODEL
Solutions & Proprietary Assets
Platform solutions and owned drug assets create multiple paths to commercialization and enterprise value.
Quantum, AI, drug discovery and finance—combined in one leadership team.
QIC’s leadership combines research credentials from Oxford, IBM T.J. Watson, KAIST, UCSF, UNIST and global pharmaceutical companies with the business experience required to translate science into industrial value.
CEO · FOUNDER
Choi Hwan-ho
MD · PhD · Quantum Chemistry · Drug Discovery
MD in Medicine, Kyunghee University · Oxford PhD in Chemistry · SNU Physics
AstraZeneca and KRIBB researcher
Advisor to the National AI CommitteeMOTIE planning-committee member
CTO · CO-FOUNDER
Kang Hong-seok
PhD · Quantum · Machine-Learning Algorithms
IBM T.J. Watson Research Center · KRIBB
University of Maryland PhD in Chemical Physics SNU Physics & Computer Science
CSO
Kevin Kim
PhD · Biophysics · Protein Structural Biology
University of California, San Francisco researcher
University of Illinois Urbana-Champaign PhD in Physics · SNU Physics
PRINCIPAL RESEARCHER
Choi Geun-su
PhD · Quantum-Chemistry Reactions · Catalysis
UNIST Research Assistant Professor · KIST and UNIST postdoctoral researcher · SK Innovation
SNU PhD in Physics
EVP · DRUG BUSINESS
Ko Bo-sung
PhD · Clinical · R&D · External Affairs
inVentiv Health VP · Dong Wha Pharm Overseas Business Director · Global pharmaceutical industry experience
Helsinki School of Economics MBA MS in Physical Pharmacy, Seoul National University BS in Pharmacy, Seoul National University
CMO
Lee Geun
Commercialization · Strategy · Marketing
LG Electronics · Samsung C&T · CJ · Megabox Head of Marketing New business planning, marketing strategy and brand communications
BA in Journalism and Mass Communication, Korea University
Four focused groups connect research and business execution.
01Business Group · CORE
Quantum Drug Group
QUEST™, candidate discovery, preclinical prediction and proprietary pipeline development.
02Business Group
Quantum Finance Group
FintelliQ™, credit intelligence, optimization and financial industry validation.
03Business Group
Quantum Chemistry Group
Quantum chemistry, molecular computation and the scientific foundation of drug discovery.
04Business Group
Management & Business Group
Strategy, business development, partnerships, marketing and corporate operations.
04 / Strategic Partnerships
World-class technology, research and industry partners.
QIC’s partnership network connects quantum infrastructure, academic expertise, experimental validation and real industry data to accelerate Quantum–AI development and application.
01GLOBAL QUANTUM
Quantum technology partners
IBM QuantumIBM Quantum Network member · Superconducting-qubit accessOQCSuperconducting-qubit platformQuEraNeutral-atom quantum computingPasqalNeutral-atom platform and industry collaborationQuandelaPhotonic quantum computing partnershipClassiqQuantum software and joint research
02QUANTUM & PHYSICS
Academic research network
SNU Hybrid Quantum Computing CenterJoint-research MOUYonsei Quantum Computing CenterQuantum-computing joint researchUNIST Quantum Research InstituteQuantum research collaborationUniversity of MinnesotaPhysics research collaboration
03DRUG DISCOVERY & CHEMISTRY
Experimental and domain partners
Korea Institute of ToxicologyRPT efficacy and toxicity validationWuXi AppTecExperimental library supporting AI discoveryD&D PharmatechOral α4β7 peptide joint developmentKyungdong PharmClinical and pharmaceutical collaborationBiotoxtech · ChemtelicPreclinical and experimental validationSNU College of MedicineClinical and medical-domain researchKAISTStructural biology and chemistry researchSungkyunkwan · Chung-Ang UniversityPharmacy and drug-delivery research
04FINANCE
Financial validation partners
NICE Information ServiceFinance-sector PoC and industry-data validationSingapore Management UniversityJoint research in quantum financeGachon UniversityQuantum-finance algorithm research
